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ABSTRACT
This study investigated the prevalence of specific Toxoplasma gondii IgG in pregnancy, the incidence of
congenital toxoplasmosis and the prevalence trend of T. gondii infection among pregnant Polish women
between 1998 and 2003. The study population comprised 4916 women who were admitted to the Polish
Mother’s Memorial Hospital Research Institute in Ło´dz´. Their sera were tested for specific IgG and IgM
antibodies to T. gondii, and the incidence of T. gondii infection was calculated from the increase in
prevalence rates of IgG antibodies in various age groups. Specific IgG antibody was found in 41.3%
(95% CI 39.9–42.7) of pregnant women, and the prevalence of IgG increased with age. The linear trend
was significant (p <0.001), with an annual seroconversion rate of 0.7% (95% CI 0.004–0.010). The risk of
primary infection was estimated to be 0.5% for 9 months, i.e., an incidence of 5 ⁄ 1000 pregnancies.
Assuming a 30% maternofetal transmission rate, 1.5 ⁄ 1000 neonates were infected in utero. Seroprev-
alence during the 6-year study period decreased from 45.4% in 1998 to 39.4% in 2003, with a yearly
decline in prevalence of 1.0% (p 0.02). The most important contributory factor to this decline was the
group of women aged 19–29 years, among whom seroprevalence decreased significantly (p 0.007).
Specific IgM was found in 244 (4.9%) women.
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INTRODUCTION
Toxoplasma gondii causes one of the most common
parasitic infections in humans [1]. The general
routes of T. gondii transmission are well-known
[2], with infection usually occurring following
ingestion of viable cysts in raw or undercooked
meat, or of oocysts shed in cat faeces; thus, eating
habits and poor hygiene are risk-factors for
toxoplasmosis [3–5]. Specific antibodies against
the parasite appear soon after primary infection.
The prevalence of T. gondii differs among coun-
tries worldwide, but also within a country [6–8].
During the last few decades, a remarkable
decrease in the prevalence has been observed
[9–11]. Since raw meat is probably one of the
major sources of T. gondii, the decrease in preval-
ence is probably related to improvements in
health education and meat processing [12]. How-
ever, the main sources of T. gondii infection in the
Polish population are unclear.
In order to plan a strategic approach for the
prevention of congenital toxoplasmosis (CT), it is
necessary to know the frequency at which preg-
nant women are infected with T. gondii [11].
Primary infection in pregnancy poses a risk of
fetal infection. The clinical picture of CT varies
(from death in utero, to neurological or eye
damage, to asymptomatic forms) and depends
mainly on the gestational age at which infection
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occurs [13]. Toxoplasmosis is an undoubted threat
during pregnancy. To better understand the mag-
nitude of the problem and the risks, the prevalence
of specific T. gondii IgG was investigated in a
population of pregnant Polish women in order to
assess the incidence of toxoplasmosis in preg-
nancy and the incidence of congenital disease.
MATERIALS AND METHODS
The study population comprised 4916 pregnant women who
attended the outpatient obstetric clinic or who were admitted
to the Polish Mother’s Memorial Hospital Research Institute
(PMMHRI) in Ło´dz´ during a 6-year period (1998–2003). In
addition to patients from the immediate vicinity, obstetric
patients from throughout Poland seek medical attention at this
institution, as it houses a specialist perinatal care centre.
Serological tests for Toxoplasma infection are recommended for
all pregnant women during the first trimester, and should be
repeated in the third trimester for those women with negative
results. However, screening for T. gondii is not obligatory in
Poland.
Serum collection
Blood samples were obtained from each pregnant woman by
venepuncture during the first visit to the PMMHRI. The
samples were centrifuged and then stored at 4C until analysis,
which was usually within 2 days.
Laboratory tests
All samples were tested at the Parasitology Unit in the
Department of Microbiology at the PMMHRI in Ło´dz´. Screen-
ing for Toxoplasma IgG antibodies was performed with an
indirect agglutination test (Toxo Screen DA; bioMe´rieux,
Warszawa, Poland), using 4 IU ⁄mL as the cut-off point.
Between January 1998 and February 2000, all positive samples
were retested with an enzyme immunoassay (Platelia Toxo-G;
Diagnostics Sanofi Pasteur, Warszawa, Poland), and were
reported in terms of IU ⁄mL. Samples with ‡6 IU ⁄mL were
considered to be positive and indicative of a previous T. gondii
infection. All samples, both IgG-positive and IgG-negative,
were tested for specific IgM by Platelia Toxo-M (Diagnostics
Sanofi Pasteur). The Platelia method was replaced by an ELISA
(Vidas Toxo IgG; bioMe´rieux) between March 2000 and
December 2003. Samples with ‡8 IU ⁄mL were considered to
be positive. The same ELISA was also used for IgM detection.
Statistical analysis
An estimate of the yearly seroconversion rate was calculated
by using a mathematical model that determined the relation-
ship between age and prevalence. Binomial regression with
identity link was used to estimate the linear trend for age.
Departures from the linear trend for age were tested by use of
the quadratic othogonal trend for age. For prevalence, 95% CIs
were calculated, assuming a binomial distribution. Differences
were considered statistically significant at the p <0.05 level.
Data were analysed with the STATA computer program
(STATA Corp., College Station, TX, USA).
RESULTS
Prevalence in different age groups
Among the total study population of 4916 preg-
nant women (aged 19–46 years, mean 26.7 years),
2030 (41.3%) had Toxoplasma IgG antibodies
(95% CI 39.9–42.7). The prevalence of specific
IgG increased significantly with age, from 37.4%
(488 ⁄ 1304) in the group aged 19–24 years to 55.1%
(65 ⁄ 118) in the group aged 40–46 years (p <0.001).
The antibody prevalence rates according to age
are shown in Fig. 1. The linear trend was signi-
ficant (p <0.001), with a yearly prevalence differ-
ence of 0.7% (95% CI 0.4–1.0). A quadratic trend
was not significant (p 0.24) for this dataset;
however, the linear trend was sufficient to des-
cribe the relationships between age and preval-
ence and the annual rate of acquisition of T. gondii
by this cohort.
Estimates of incidence
Considering an annual seroconversion rate in-
crease of 0.7%, the risk of primary infection in a
pregnancy lasting an average of 9 months was
0.5% (0.7% · (9 ⁄ 12)) (Fig. 1). Thus, the estimated
incidence of acquired infection during pregnancy
was 5 ⁄ 1000 pregnancies. Overall, among the total
group of 4916 pregnant women, 24.6 cases of
primary infection were estimated.
It was also estimated that 40% of children born
to women with a primary Toxoplasma infection
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Fig. 1. Incidence rate of Toxoplasma gondii IgG in 4916
pregnant women; estimation model based on the depend-
ency between age and prevalence, with a yearly serocon-
version rate of 0.7%.
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during pregnancy would also be infected [11].
Thus, in the study population, 9.8 neonates
would be infected in utero, i.e., 2 ⁄ 1000. Assuming
a maternofetal transmission rate of 30% [14–16],
7.38 neonates (1.5 ⁄ 1000) would be born with CT.
Taking into account the 95% CIs for the yearly
0.7% prevalence difference, the yearly serocon-
version rate ranged from 0.4% to 1.0%. Thus, the
risk of primary infection during a 9-month preg-
nancy would be 0.3–0.75%, and the incidence of
infection in pregnancy would range from 3.0 ⁄ 1000
to 7.5 ⁄ 1000. In the total study population, the
primary infection affected between 14.7 and 36.9
women. Assuming maternofetal transmission
rates of either 40% or 30%, between 5.9 and
14.8 (1.2 ⁄ 1000–3.0 ⁄ 1000), or between 4.4 and 11.1
(0.9 ⁄ 1000–2.3 ⁄ 1000) neonates, respectively, would
have been infected in utero.
Prevalence rates between 1998 and 2003
Between 1998 and 2003, the prevalence of T. gon-
dii IgG in pregnant Polish women decreased from
45.4% to 39.4% (Table 1). The decreasing trend
during the 6-year period was significant (p 0.02).
The annual decline in seroprevalence was esti-
mated at 1.0%; when adjusted for age, the yearly
prevalence difference was slightly higher (1.1%;
p 0.01).
The yearly decreasing trend in seroprevalence
did not differ significantly among the age groups
(p 0.08). However, since the difference nearly
reached significance, the trend was tested for
each age group separately. A significant (95% CI
) 0.025 — )0.004; p 0.007) decreasing trend was
found between 1998 and 2003 for the youngest
group of women (aged 19–29 years), but no
significant difference was observed for other
age groups.
Prevalence of IgM antibodies
Specific IgM antibodies were detected in 244
(4.9%) women (95% CI 4.4–5.6).
DISCUSSION
Toxoplasma IgG seroprevalence differs throughout
the world [6]. In Europe, the highest rates are
observed in the central and southern regions,
while the lowest rates are found in the northern
regions [17]. High seroprevalence rates, reaching
70%, have been described previously in Poland
[18–22]. Seroprevalence rates of 59%, 57% and
46% have been described in forestry workers
(mean age 40 years) and farmers (41 years) from
the Lublin region (eastern Poland) and the Lublin
population (35 years), respectively [23]. In 1998,
44% of 1920 pregnant women from the Ło´dz´
region were seropositive [24]. The present study
found a seroprevalence of 41.3% among 4916
pregnant women attending the PMMHRI in Ło´dz´.
Interestingly, a decreasing prevalence trend of
specific IgG was observed, from 45.4% in 1998 to
39.4% in 2003. A similar decrease was observed in
the Poznan´ region between 1990 and 2000, from
58.9% to 43.7% [25], and also in other European
countries [9–11,26–32].
The main reason for the annual 1% decline in
seroprevalence was the significant decrease in
seroprevalence among the youngest group of
women (aged 19–29 years). Similarly, Kortbeek
et al. [33] reported lower seroprevalence rates
among women aged 15–49 years between 1995
and 1996 than in 1987 or 1988. This may reflect the
changes in nutritional habits that have taken place
in Poland during the last few years. The wide
access to fast-foods and pre-prepared meals,
including frozen meat meals, and the decreasing
number of home-prepared meals, may have
contributed to the overall reduction in T. gondii
acquisition among younger women, but the
decrease in seroprevalence could be also related
to better primary prevention [13,34].
The overall prevalence of 41.3%may be a slight
overestimation, since the data in the present study
were collected from a referral centre in Poland.
The hospital offers obstetrical care and focuses on
treatment of at-risk pregnancies and therapy for
fetal disorders. Fetal malformations occur gener-
ally in only 5–10% of cases with CT [11], but the
high percentage of fetal defects in the population
Table 1. Prevalence of Toxoplasma gondii IgG antibodies
among pregnant women tested in Ło´dz´, Poland, each year
between 1998 and 2003 (n = number of women)
Year Total n
IgG-positive
Mean agen % 95% CI
1998 562 255 45.4 41.2–49.6 27.7
1999 682 312 45.8 42.0–49.6 27.1
2000 788 293 37.2 33.8–40.7 27.7
2001 965 395 40.9 37.8–44.1 27.9
2002 940 389 41.4 38.2–44.6 27.6
2003 979 386 39.4 36.4–44.6 28.0
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studied at the PMMHRI may have influenced the
overall rate of Toxoplasma seroprevalence.
The risk of acquisition of T. gondii is thought to
be the same at any age [11]. The present study
used an estimation model of the dependence
between age and prevalence to calculate the
yearly seroconversion rate. The referral bias does
not influence the trend of the yearly seroconver-
sion rate or the estimated incidence in pregnant
women, nor does it change the trend in T. gondii
prevalence observed during the course of a few
years or in a certain age group. Similarly, the
incidence of CT based on the maternofetal trans-
mission rate is not biased. Assuming a materno-
fetal transmission rate of 40% [11], two infected
neonates would be expected for every 1000
women. Thus, the incidence of at least 0.55 ⁄ 1000
live births in the Poznan region was lower than
the incidence estimated in the present study.
However, serological screening of neonates does
not detect the majority of infants infected before
the 20th week of pregnancy [35]. Neonatal screen-
ing is a useful tool for an early diagnosis when the
risk of primary infection is lower [36], as seen in
population-based cohort studies from Finland
(1988–1989) and Denmark (1992–1996), in which
CT occurred with incidences of 2.4 ⁄ 10 000 and
3.0 ⁄ 10 000, respectively [37,38].
The present study also detected a 5% preval-
ence of Toxoplasma IgM antibodies. This means
that nearly 50 ⁄ 1000 women had detectable IgM
during pregnancy; however, the estimated inci-
dence of primary infection was 5 ⁄ 1000 pregnan-
cies. These results may reflect the common
occurrence of persistent IgM for at least 1 year
after acquisition [39]. Women are frequently
retested at the PMMHRI to confirm previous
serological results that suggest recent T. gondii
infection. During the natural evolution of the
infection, specific Toxoplasma IgM appears before
specific IgG. In the present study of 4916 pregnant
women, specific IgM without IgG was detected in
only two (0.04%) cases.
The seroprevalence of T. gondii in Poland is
sufficiently high to warrant the attention of
healthcare specialists. Pre-natal screening for
toxoplasmosis has not been introduced in Poland
[25]; however, the prevalence of primary T. gondii
infection among pregnant Polish women is com-
parable to or higher than that in countries that use
this strategic approach. Severe forms of CT are
still observed in Poland [40]. There is a need for a
pilot national screening project to determine the
burden of Toxoplasma infection during pregnancy
in Poland.
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